BrainStorm decimated by ALS failure

Tuesday was a share-splitting day for US biotech BrainStorm Cell Therapeutics (Nasdaq: BCLI).

The company announced top-line results from its randomized, double-blind placebo-controlled trial evaluating NurOwn (MSC-NTF cells) as a treatment for amyotrophic lateral sclerosis (ALS).

In the Phase III trial, the primary efficacy endpoint was a responder analysis evaluating the proportion of participants who experienced a 1.25 points per month improvement in the post-treatment revised ALS functional rating scale (ALSFRS-R) slope.